• Citing Article List

    The journal uses Crossref Cited-by service counts times cited of published articles. Cited-by allows Crossref members to find out who is citing their content. This is the Citing Article List of “Perspectives of nonalcoholic fatty liver disease research: a personal point of view”.
    No. Publication Date Citing Article
    1 2022 Joud Alalwani, Sereen Eljazzar, Maya Basil, Reema Tayyem. The impact of health status, diet and lifestyle on non‐alcoholic fatty liver disease: Narrative review, Clinical Obesity. 2022; 12: e12525.  https://doi.org/10.1111/cob.12525
    2 2024 Bingwu Xu, Cuihong Li, Mengxue Chen, Yong Zhang. Four hepatic steatosis indices in predicting quantitative computed tomography-based metabolic dysfunction-associated fatty liver disease, Exploration of Endocrine and Metabolic Diseases. 2024; 1: 62.  https://doi.org/10.37349/eemd.2024.00008
    3 2023 Alan L. Hutchison, Federica Tavaglione, Stefano Romeo, Michael Charlton. Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): Beyond insulin resistance, Journal of Hepatology. 2023; 79: 1524.  https://doi.org/10.1016/j.jhep.2023.08.030
    4 2023 Amedeo Lonardo, Principles of risk stratification in nonalcoholic fatty liver disease. A narrative review emphasizing non-invasive strategies, Exploration of Digestive Diseases. 2023; 188.  https://doi.org/10.37349/edd.2023.00026
    5 2021 Amedeo Lonardo, Renaming NAFLD to MAFLD: Could the LDE System Assist in This Transition?, Journal of Clinical Medicine. 2021; 10: 492.  https://doi.org/10.3390/jcm10030492
    6 2020 Jessica Binetti, Laia Bertran, David Riesco, Carmen Aguilar, Salomé Martínez, Fàtima Sabench, Jose Antonio Porras, Javier Camaron, Daniel Del Castillo, Cristóbal Richart, Teresa Auguet. Deregulated Serotonin Pathway in Women with Morbid Obesity and NAFLD, Life. 2020; 10: 245.  https://doi.org/10.3390/life10100245
    7 2022 Hanzhang Wu, Xiaolu He, Qian Li, Yunliang Zheng, Sabina Rayamajhi, Amrish Thapa, Ge Meng, Qing Zhang, Li Liu, Hongmei Wu, Yeqing Gu, Shunming Zhang, Tingjing Zhang, Xuena Wang, Juanjuan Zhang, Zhixia Cao, Jun Dong, Xiaoxi Zheng, Xu Zhang, Xinrong Dong, Shaomei Sun, Xing Wang, Ming Zhou, Qiyu Jia, Kun Song, Hong Chang, Kaijun Niu. Relationship between the consumption of wholegrain and nonalcoholic fatty liver disease: The TCLSIH cohort study, Clinical Nutrition. 2022; 41: 1483.  https://doi.org/10.1016/j.clnu.2022.05.009
    8 2023 Stefano Ballestri, Amedeo Lonardo. Ultrasonographic fatty liver indicator (US-FLI): a reliable biomarker for non-invasive NAFLD stratification, Metabolism and Target Organ Damage. 2023; 3:   https://doi.org/10.20517/mtod.2023.21
    9 2020 Clarissa Berardo, Laura Giuseppina Di Pasqua, Marta Cagna, Plinio Richelmi, Mariapia Vairetti, Andrea Ferrigno. Nonalcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: Current Issues and Future Perspectives in Preclinical and Clinical Research, International Journal of Molecular Sciences. 2020; 21: 9646.  https://doi.org/10.3390/ijms21249646
    10 2020 Amedeo Lonardo, Simona Leoni, Khalid A. Alswat, Yasser Fouad. History of Nonalcoholic Fatty Liver Disease, International Journal of Molecular Sciences. 2020; 21: 5888.  https://doi.org/10.3390/ijms21165888
    11 2022 Amedeo Lonardo, Precision medicine in nonalcoholic fatty liver disease, Journal of Gastroenterology and Hepatology. 2022; 37: 1175.  https://doi.org/10.1111/jgh.15850
    12 2022 Xiao-fei Tong, Qian-yi Wang, Xin-yan Zhao, Ya-meng Sun, Xiao-ning Wu, Li-ling Yang, Zheng-zhao Lu, Xiao-juan Ou, Ji-dong Jia, Hong You. Histological assessment based on liver biopsy: the value and challenges in NASH drug development, Acta Pharmacologica Sinica. 2022; 43: 1200.  https://doi.org/10.1038/s41401-022-00874-x
    13 2023 Donghee Kim, Brittany B. Dennis, George Cholankeril, Aijaz Ahmed. Association between depression and metabolic dysfunction-associated fatty liver disease/significant fibrosis, Journal of Affective Disorders. 2023; 329: 184.  https://doi.org/10.1016/j.jad.2023.02.101
    14 2023 Piero Portincasa, NAFLD, MAFLD, and beyond: one or several acronyms for better comprehension and patient care, Internal and Emergency Medicine. 2023; 18: 993.  https://doi.org/10.1007/s11739-023-03203-0
    15 2021 Amedeo Lonardo, Juan Pablo Arab, Marco Arrese. Perspectives on Precision Medicine Approaches to NAFLD Diagnosis and Management, Advances in Therapy. 2021; 38: 2130.  https://doi.org/10.1007/s12325-021-01690-1
    16 2021 Stefano Ballestri, Alessandro Mantovani, Enrica Baldelli, Simonetta Lugari, Mauro Maurantonio, Fabio Nascimbeni, Alessandra Marrazzo, Dante Romagnoli, Giovanni Targher, Amedeo Lonardo. Liver Fibrosis Biomarkers Accurately Exclude Advanced Fibrosis and Are Associated with Higher Cardiovascular Risk Scores in Patients with NAFLD or Viral Chronic Liver Disease, Diagnostics. 2021; 11: 98.  https://doi.org/10.3390/diagnostics11010098
    17 2021 Amedeo Lonardo, Separating the apples from the oranges: from NAFLD heterogeneity to personalized medicine, Exploration of Medicine. 2021;   https://doi.org/10.37349/emed.2021.00061
    18 2022 Dante Romagnoli, Elimination of hepatitis C virus infection in Europe: targeting the obstacles, Exploration of Medicine. 2022; 71.  https://doi.org/10.37349/emed.2022.00075
    19 2020 Óscar Soto-Angona, Gerard Anmella, María José Valdés-Florido, Nieves De Uribe-Viloria, Andre F. Carvalho, Brenda W. J. H. Penninx, Michael Berk. Non-alcoholic fatty liver disease (NAFLD) as a neglected metabolic companion of psychiatric disorders: common pathways and future approaches, BMC Medicine. 2020; 18: 261.  https://doi.org/10.1186/s12916-020-01713-8
    20 2023 Mirah Khalid Alshehhi, Asiya Nazir. 2023; 139.  https://doi.org/10.1016/B978-0-323-99336-4.00010-0
    21 2023 Yongyuan He, Yinghong Su, Chengcheng Duan, Siyuan Wang, Wei He, Yingting Zhang, Xiaofei An, Ming He. Emerging role of aging in the progression of NAFLD to HCC, Ageing Research Reviews. 2023; 84: 101833101833.  https://doi.org/10.1016/j.arr.2022.101833
    22 2023 Oana Petrea, Gabriela Stefanescu, Cristinel Stefanescu. 2023; 203.  https://doi.org/10.1007/978-3-031-33548-8_18
    23 2023 Amedeo Lonardo, Iron depletion in “metabolic fatty liver syndromes”: a strong biological rationale with disappointing liver outcomes, Exploration of Drug Science. 2023; 239.  https://doi.org/10.37349/eds.2023.00016
    24 2023 Amedeo Lonardo, MASLD co-aggregates with HCC in families-names change, fa(c)ts remain, Hepatoma Research. 2023;   https://doi.org/10.20517/2394-5079.2023.110